CYP2C19 Metabolizer Status and Clopidogrel Efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) Study

被引:50
作者
McDonough, Caitrin W. [1 ,2 ]
McClure, Leslie A. [4 ]
Mitchell, Braxton D. [5 ,7 ]
Gong, Yan [1 ,2 ]
Horenstein, Richard B. [5 ,6 ]
Lewis, Joshua P. [5 ,6 ]
Field, Thalia S. [8 ]
Talbert, Robert L. [9 ]
Benavente, Oscar R. [8 ]
Johnson, Julie A. [1 ,2 ,3 ]
Shuldiner, Alan R. [5 ,6 ,7 ]
机构
[1] Univ Florida, Dept Pharmacotherapy & Translat Res, Gainesville, FL USA
[2] Univ Florida, Ctr Pharmacogen, Coll Pharm, Gainesville, FL USA
[3] Univ Florida, Coll Med, Div Cardiovasc Med, Gainesville, FL USA
[4] Univ Alabama Birmingham, Dept Biostat, Sch Publ Hlth, Birmingham, AL 35294 USA
[5] Univ Maryland, Sch Med, Div Endocrinol Diabet & Nutr, Baltimore, MD USA
[6] Univ Maryland, Sch Med, Program Personalized & Genom Med, Baltimore, MD USA
[7] Vet Adm Med Ctr, Geriatr Res & Educ Clin Ctr, Baltimore, MD 21218 USA
[8] Univ British Columbia, Dept Neurol, Vancouver, BC V5Z 1M9, Canada
[9] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA
来源
JOURNAL OF THE AMERICAN HEART ASSOCIATION | 2015年 / 4卷 / 06期
关键词
clopidogrel; CYP2C19; pharmacogenomics; stroke prevention; subcortical stroke; IMPLEMENTATION CONSORTIUM GUIDELINES; ADVERSE CLINICAL-OUTCOMES; ISCHEMIC-STROKE; MULTIETHNIC POPULATION; PERSONALIZED MEDICINE; ASSOCIATION; GENOTYPE; SUBTYPES; LACUNAR; PHARMACOGENETICS;
D O I
10.1161/JAHA.114.001652
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-The role of the CYP2C19 genotype on clopidogrel efficacy has been studied widely, with data suggesting reduced clopidogrel efficacy in loss-of-function variant carriers taking clopidogrel after percutaneous coronary intervention; however, data are limited regarding the association between CYP2C19 genetic variants and outcomes in stroke patients. We investigated whether CYP2C19 metabolizer status affects the risk of recurrent stroke or major bleeding in subcortical stroke patients taking dual antiplatelet therapy with aspirin and clopidogrel. Methods and Results-CYP2C19*2 and CYP2C19*17 were genotyped in 522 patients treated with dual antiplatelet therapy from the Secondary Prevention of Small Subcortical Strokes (SPS3) study. CYP2C19 metabolizer status was inferred from genotype, and associations with the risk of recurrent stroke and major bleeding were assessed in the overall cohort and by race/ethnic group with logistic regression modeling. In the overall cohort, there were no differences in outcomes by CYP2C19 metabolizer status (recurrent stroke, odds ratio 1.81 [95% CI 0.76 to 4.30]; major bleeding, odds ratio 0.67 [95% CI 0.22 to 2.03]). In white participants, those with CYP2C19 intermediate or poor metabolizer status had higher odds of recurrent stroke (odds ratio 5.19 [95% CI 1.08 to 24.90]) than those with extensive or ultrarapid metabolizer status, but there was no evidence of difference in major bleeding. Conclusions-There were significant differences in recurrent stroke by CYP2C19 genotype-inferred metabolizer status in white subcortical stroke patients receiving dual antiplatelet therapy with aspirin and clopidogrel, consistent with cardiovascular studies on CYP2C19 and clopidogrel; however, the bleeding risk that led to early termination of the antiplatelet arm of the SPS3 trial does not appear to be explained by CYP2C19 genotype. This study was relatively underpowered; therefore, these findings should be interpreted with caution and warrant replication.
引用
收藏
页数:7
相关论文
共 42 条
[1]   A map of human genome variation from population-scale sequencing [J].
Altshuler, David ;
Durbin, Richard M. ;
Abecasis, Goncalo R. ;
Bentley, David R. ;
Chakravarti, Aravinda ;
Clark, Andrew G. ;
Collins, Francis S. ;
De la Vega, Francisco M. ;
Donnelly, Peter ;
Egholm, Michael ;
Flicek, Paul ;
Gabriel, Stacey B. ;
Gibbs, Richard A. ;
Knoppers, Bartha M. ;
Lander, Eric S. ;
Lehrach, Hans ;
Mardis, Elaine R. ;
McVean, Gil A. ;
Nickerson, DebbieA. ;
Peltonen, Leena ;
Schafer, Alan J. ;
Sherry, Stephen T. ;
Wang, Jun ;
Wilson, Richard K. ;
Gibbs, Richard A. ;
Deiros, David ;
Metzker, Mike ;
Muzny, Donna ;
Reid, Jeff ;
Wheeler, David ;
Wang, Jun ;
Li, Jingxiang ;
Jian, Min ;
Li, Guoqing ;
Li, Ruiqiang ;
Liang, Huiqing ;
Tian, Geng ;
Wang, Bo ;
Wang, Jian ;
Wang, Wei ;
Yang, Huanming ;
Zhang, Xiuqing ;
Zheng, Huisong ;
Lander, Eric S. ;
Altshuler, David L. ;
Ambrogio, Lauren ;
Bloom, Toby ;
Cibulskis, Kristian ;
Fennell, Tim J. ;
Gabriel, Stacey B. .
NATURE, 2010, 467 (7319) :1061-1073
[2]   THE NATURAL-HISTORY OF LACUNAR INFARCTION - THE OXFORDSHIRE COMMUNITY STROKE PROJECT [J].
BAMFORD, J ;
SANDERCOCK, P ;
JONES, L ;
WARLOW, C .
STROKE, 1987, 18 (03) :545-551
[3]   Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial [J].
Benavente, O. R. ;
Coffey, C. S. ;
Conwit, R. ;
Hart, R. G. ;
McClure, L. A. ;
Pearce, L. A. ;
Pergola, P. E. ;
Szychowski, J. M. ;
Benavente, O. R. ;
Hart, R. G. ;
Pergola, P. E. ;
Palacio, S. ;
Castro, I. ;
Farias, A. ;
Roldan, A. ;
Kase, C. ;
Gavras, I. ;
Lau, H. ;
Ogrodnik, M. ;
Allen, N. ;
Meissner, I. ;
Graves, J. ;
Herzig, D. ;
Covalt, J. ;
Meyer, B. ;
Jackson, C. ;
Gamble, P. ;
Kelly, N. ;
Warner, J. ;
Bell, J. ;
Demaerschalk, B. ;
Hogan, M. ;
Wochos, D. ;
Wieser, J. ;
Cleary, B. ;
Wood, L. ;
Hanna, J. ;
Zipp, T. ;
Bailey, S. ;
Cook, D. ;
Liskay, A. ;
Simcox, D. ;
Kappler, J. ;
Anderson, D. ;
Grimm, R. ;
Brauer, D. ;
Pettigrew, C. ;
Vaishnov, A. ;
Sawaya, P. ;
Fowler, A. .
LANCET, 2013, 382 (9891) :507-515
[4]   Effects of Clopidogrel Added to Aspirin in Patients with Recent Lacunar Stroke [J].
Benavente, Oscar R. ;
Hart, Robert G. ;
McClure, Leslie A. ;
Szychowski, Jeffrey M. ;
Coffey, Christopher S. ;
Pearce, Lesly A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (09) :817-825
[5]   The Secondary Prevention of Small Subcortical Strokes (SPS3) study [J].
Benavente, Oscar R. ;
White, Carole L. ;
Pearce, Lesly ;
Pergola, Pablo ;
Roldan, Ana ;
Benavente, Marie-France ;
Coffey, Christopher ;
McClure, Leslie A. ;
Szychowski, Jeff M. ;
Conwit, Robin ;
Heberling, Patricia A. ;
Howard, George ;
Bazan, Carlos ;
Vidal-Pergola, Gabriela ;
Talbert, Robert ;
Hart, Robert G. .
INTERNATIONAL JOURNAL OF STROKE, 2011, 6 (02) :164-175
[6]   THE LAUSANNE STROKE REGISTRY - ANALYSIS OF 1,000 CONSECUTIVE PATIENTS WITH 1ST STROKE [J].
BOGOUSSLAVSKY, J ;
VANMELLE, G ;
REGLI, F .
STROKE, 1988, 19 (09) :1083-1092
[7]   PROGNOSIS FOR SURVIVAL, HANDICAP AND RECURRENCE OF STROKE IN LACUNAR AND SUPERFICIAL INFARCTION [J].
BOITEN, J ;
LODDER, J .
CEREBROVASCULAR DISEASES, 1993, 3 (04) :221-226
[8]   STROKE SUBTYPES AMONG HISPANICS LIVING IN GUAYAQUIL, ECUADOR - RESULTS FROM THE LUIS-VERNAZA-HOSPITAL STROKE REGISTRY [J].
DELBRUTTO, OH ;
MOSQUERA, A ;
SANCHEZ, X ;
SANTOS, J ;
NOBOA, CA .
STROKE, 1993, 24 (12) :1833-1836
[9]  
Herbert Jean-Marc, 2003, Semin Vasc Med, V3, P113
[10]   Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19*2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration A Systematic Meta-Analysis [J].
Hulot, Jean-Sebastien ;
Collet, Jean-Philippe ;
Silvain, Johanne ;
Pena, Ana ;
Bellemain-Appaix, Anne ;
Barthelemy, Olivier ;
Cayla, Guillaume ;
Beygui, Farzin ;
Montalescot, Gilles .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 56 (02) :134-143